Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 5/20 | 0.33 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14818473 | 1.00 | LAP3 (0.33) | LAP3ANPEPERAP1RNPEPSLC7A5 | |
| SCHEMBL4476335 | 1.00 | LAP3 (0.33) | LAP3ANPEPERAP1RNPEPSLC7A5 | |
| SCHEMBL12951695 | 0.82 | MMP1 (0.35) | — | |
| SCHEMBL14299587 | 0.82 | MMP1 (0.35) | — | |
| SCHEMBL3939885 | 0.79 | LMNA (0.31) | — | |
| SCHEMBL11460321 | 0.78 | — | — | |
| SCHEMBL11851600 | 0.78 | FDPS (0.39) | — | |
| SCHEMBL23346288 | 0.76 | — | — | |
| SCHEMBL11316721 | 0.76 | FDPS (0.42) | — | |
| SCHEMBL7941316 | 0.76 | FDPS (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328057-B2 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | DOMPE PHA.R.MA S.P.A. (IT) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | NR1H4, MMP8, NR1I2 | LAP3 2607/4885ANPEP 3280/4885ERAP1 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.